Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

български (BG) (302.02 KB - PDF)

View

español (ES) (354.71 KB - PDF)

View

čeština (CS) (398.51 KB - PDF)

View

dansk (DA) (353.81 KB - PDF)

View

Deutsch (DE) (356.65 KB - PDF)

View

eesti keel (ET) (353.06 KB - PDF)

View

ελληνικά (EL) (422.14 KB - PDF)

View

français (FR) (356.76 KB - PDF)

View

hrvatski (HR) (377.01 KB - PDF)

View

italiano (IT) (353.82 KB - PDF)

View

latviešu valoda (LV) (406.74 KB - PDF)

View

lietuvių kalba (LT) (379.26 KB - PDF)

View

magyar (HU) (396.03 KB - PDF)

View

Malti (MT) (409.42 KB - PDF)

View

Nederlands (NL) (354.93 KB - PDF)

View

polski (PL) (399.96 KB - PDF)

View

português (PT) (355.88 KB - PDF)

View

română (RO) (378.84 KB - PDF)

View

slovenčina (SK) (399.95 KB - PDF)

View

slovenščina (SL) (388.87 KB - PDF)

View

Suomi (FI) (352.89 KB - PDF)

View

svenska (SV) (354.63 KB - PDF)

View

Product information

български (BG) (711.12 KB - PDF)

View

español (ES) (810.61 KB - PDF)

View

čeština (CS) (932.35 KB - PDF)

View

dansk (DA) (807.39 KB - PDF)

View

Deutsch (DE) (801.97 KB - PDF)

View

eesti keel (ET) (803.1 KB - PDF)

View

ελληνικά (EL) (1.13 MB - PDF)

View

français (FR) (922.81 KB - PDF)

View

hrvatski (HR) (822.66 KB - PDF)

View

íslenska (IS) (810.01 KB - PDF)

View

italiano (IT) (806.79 KB - PDF)

View

latviešu valoda (LV) (957.91 KB - PDF)

View

lietuvių kalba (LT) (826.73 KB - PDF)

View

magyar (HU) (938.04 KB - PDF)

View

Malti (MT) (965.75 KB - PDF)

View

Nederlands (NL) (902.64 KB - PDF)

View

norsk (NO) (808.14 KB - PDF)

View

polski (PL) (926.02 KB - PDF)

View

português (PT) (810.56 KB - PDF)

View

română (RO) (837.75 KB - PDF)

View

slovenčina (SK) (936.99 KB - PDF)

View

slovenščina (SL) (973.11 KB - PDF)

View

Suomi (FI) (837.29 KB - PDF)

View

svenska (SV) (805.16 KB - PDF)

View

Latest procedure affecting product information: IG/0855/G

24/11/2017

български (BG) (336.55 KB - PDF)

View

español (ES) (278.67 KB - PDF)

View

čeština (CS) (308.83 KB - PDF)

View

dansk (DA) (281.18 KB - PDF)

View

Deutsch (DE) (281.33 KB - PDF)

View

eesti keel (ET) (279.45 KB - PDF)

View

ελληνικά (EL) (312.94 KB - PDF)

View

français (FR) (278.12 KB - PDF)

View

hrvatski (HR) (296.78 KB - PDF)

View

íslenska (IS) (277.37 KB - PDF)

View

italiano (IT) (277.07 KB - PDF)

View

latviešu valoda (LV) (305.14 KB - PDF)

View

lietuvių kalba (LT) (299.06 KB - PDF)

View

magyar (HU) (289.49 KB - PDF)

View

Malti (MT) (304.2 KB - PDF)

View

Nederlands (NL) (277.85 KB - PDF)

View

norsk (NO) (278.69 KB - PDF)

View

polski (PL) (305.13 KB - PDF)

View

português (PT) (278.81 KB - PDF)

View

română (RO) (299.89 KB - PDF)

View

slovenčina (SK) (303.57 KB - PDF)

View

slovenščina (SL) (302.35 KB - PDF)

View

Suomi (FI) (275.1 KB - PDF)

View

svenska (SV) (277.71 KB - PDF)

View

Product details

Name of medicine
Ingelvac PCV FLEX
Active substance
porcine circovirus type 2 ORF2 protein
International non-proprietary name (INN) or common name
Porcine circovirus vaccine (inactivated)
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) code
QI09AA07

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

For active immunisation of pigs with no PCV2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (PCV2)

Authorisation details

EMA product number
EMEA/V/C/004645
Marketing authorisation holder
Boehringer Ingelheim Vetmedica GmbH

Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Opinion adopted
16/03/2017
Marketing authorisation issued
24/05/2017
Revision
2

Assessment history

This page was last updated on

Share this page